Expression and characterisation of finger protease (FP); a mutant tissue-type plasminogen activator (t-PA) with improved pharmacokinetics

[1]  C. D. de Vries,et al.  Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin. , 1989, The Journal of biological chemistry.

[2]  G. Larsen,et al.  Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. , 1989, Blood.

[3]  E. Ohlstein,et al.  Attenuation of the inhibitory effect of prostacyclin on platelet function after tissue plasminogen activator or streptokinase infusion in the rabbit , 1989 .

[4]  R. Shebuski,et al.  Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. , 1988, Thrombosis research.

[5]  J. Trill,et al.  DHFR coamplification of t-PA in DHFR+ bovine endothelial cells: in vitro characterization of the purified serine protease. , 1988, DNA.

[6]  J. Sambrook,et al.  Variants of human tissue‐type plasminogen activator that lack specific structural domains of the heavy chain. , 1988, The EMBO journal.

[7]  H. Pannekoek,et al.  Mutants of human tissue-type plasminogen activator (t-PA): Structural aspects and functional properties , 1988 .

[8]  P. Hung,et al.  Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. , 1988, The Journal of biological chemistry.

[9]  B. Reavy,et al.  A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain. , 1988, The Journal of biological chemistry.

[10]  G. Larsen,et al.  Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains. , 1988, The Journal of biological chemistry.

[11]  H. Ehrlich,et al.  Biological properties of a kringleless tissue plasminogen activator (t-PA) mutant , 1987 .

[12]  D. Collen,et al.  Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. , 1987, The Journal of laboratory and clinical medicine.

[13]  A. V. van Zonneveld,et al.  On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. , 1986, The Journal of biological chemistry.

[14]  A. V. van Zonneveld,et al.  Autonomous functions of structural domains on human tissue-type plasminogen activator. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Pfarr,et al.  A highly modular cloning vector for the analysis of eukaryotic genes and gene regulatory elements. , 1985, DNA.

[16]  H Bando,et al.  Expression in E. coli of finger‐domain lacking tissue‐type plasminogen activator with high fibrin affinity , 1985, FEBS letters.

[17]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[18]  P. Leder,et al.  Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Pennica,et al.  Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. , 1984, The Journal of pharmacology and experimental therapeutics.

[20]  R. Lyons,et al.  Requirement for the 3' flanking region of the bovine growth hormone gene for accurate polyadenylylation. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R Gomeni,et al.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation. , 1984, Computers in biology and medicine.

[22]  J. Verheijen,et al.  Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanogen bromide fragment FCB-2. , 1983, Biochimica et biophysica acta.

[23]  P. Seeburg,et al.  Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli , 1983, Nature.

[24]  I. Pastan,et al.  The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Hoylaerts,et al.  Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. , 1982, The Journal of biological chemistry.

[26]  D. Collen.  On the Regulation and Control of Fibrinolysis , 1980, Thrombosis and Haemostasis.

[27]  M. Vuento,et al.  Dissociation of fibronectin from gelatin-agarose by amino compounds. , 1978, The Biochemical journal.

[28]  D. Heene,et al.  Reduction of insolubilized fibrinogen. , 1974, Thrombosis research.

[29]  S. Iwanaga,et al.  A simple, large scale method for preparation of plasminogen-free fibrinogen , 1972 .